PremiumThe FlyExelixis upgraded to Overweight from Equal Weight at Stephens More data needed to determine Exelixis’ competitive positioning, says BofA Exelixis price target raised to $55 from $43 at Truist PremiumRatingsPromising Clinical Data and Favorable Safety Profile Drive Buy Rating for Exelixis Exelixis price target raised to $47 from $40 at H.C. Wainwright Exelixis price target raised to $46 from $45 at BofA PremiumRatingsPromising Outlook for Exelixis: Buy Rating Backed by Zanzalintinib’s Efficacy and Anticipated Phase III Trial Success Exelixis announces results from expansion cohort of STELLAR-002 trial Biotech Alert: Searches spiking for these stocks today 
